Literature DB >> 29545904

Sizes and Sufficient Quantities of MSC Microspheres for Intrathecal Injection to Modulate Inflammation in Spinal Cord Injury.

Suneel Kumar1, Joanne Babiarz1, Sayantani Basak1, Jae Hwan Kim2, Jeffrey Barminko3, Andrea Gray4, Parry Mendapara1, Rene Schloss4, Martin L Yarmush4, Martin Grumet5.   

Abstract

Microencapsulation of mesenchymal stem cells (MSC) in alginate facilitates cell delivery, localization and survival, and modulates inflammation in vivo. However, we found that delivery of the widely used ~0.5 mm diameter encapsulated MSC (eMSC) by intrathecal injection into spinal cord injury (SCI) rats was highly variable. Injections of smaller (~0.2 mm) diameter eMSC into the lumbar spine were much more reproducible and they increased the anti-inflammatory macrophage response around the SCI site. We now report that injection of small eMSC >2 cm caudal from the rat SCI improved locomotion and myelin preservation 8 weeks after rat SCI versus control injections. Because preparation of sufficient quantities of small eMSC for larger studies was not feasible and injection of the large eMSC is problematic, we have developed a procedure to prepare medium-sized eMSC (~0.35 mm diameter) that can be delivered more reproducibly into the lumbar rat spine. The number of MSC incorporated/capsule in the medium sized capsules was ~5-fold greater than that in small capsules and the total yield of eMSC was ~20-fold higher than that for the small capsules. Assays with all three sizes of eMSC capsules showed that they inhibited TNF-α secretion from activated macrophages in co-cultures, suggesting no major difference in their anti-inflammatory activity in vitro. The in vivo activity of the medium-sized eMSC was tested after injecting them into the lumbar spine 1 day after SCI. Histological analyses 1 week later showed that eMSC reduced levels of activated macrophages measured by IB4 staining and increased white matter sparing in similar regions adjacent to the SCI site. The combined results indicate that ~0.35 mm diameter eMSC reduced macrophage inflammation in regions where white matter was preserved during critical early phases after SCI. These techniques enable preparation of eMSC in sufficient quantities to perform pre-clinical SCI studies with much larger numbers of subjects that will provide functional analyses of several critical parameters in rodent models for CNS inflammatory injury.

Entities:  

Keywords:  Microcapsules; alginate; inflammation; intrathecal; mesenchymal stem cells

Year:  2015        PMID: 29545904      PMCID: PMC5849255          DOI: 10.1142/S179398441550004X

Source DB:  PubMed          Journal:  Nano Life        ISSN: 1793-9844


  40 in total

1.  Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome.

Authors:  Misuzu Osaka; Osamu Honmou; Tomohiro Murakami; Tadashi Nonaka; Kiyohiro Houkin; Hirofumi Hamada; Jeffery D Kocsis
Journal:  Brain Res       Date:  2010-05-12       Impact factor: 3.252

Review 2.  Mesenchymal stem cell treatment for autoimmune diseases: a critical review.

Authors:  Fernando E Figueroa; Flavio Carrión; Sandra Villanueva; Maroun Khoury
Journal:  Biol Res       Date:  2012       Impact factor: 5.612

Review 3.  A systematic review of cellular transplantation therapies for spinal cord injury.

Authors:  Wolfram Tetzlaff; Elena B Okon; Soheila Karimi-Abdolrezaee; Caitlin E Hill; Joseph S Sparling; Jason R Plemel; Ward T Plunet; Eve C Tsai; Darryl Baptiste; Laura J Smithson; Michael D Kawaja; Michael G Fehlings; Brian K Kwon
Journal:  J Neurotrauma       Date:  2010-04-20       Impact factor: 5.269

4.  Long-term changes in neuronal degeneration and microglial activation in the hippocampal CA1 region after experimental transient cerebral ischemic damage.

Authors:  Choong Hyun Lee; Seung Myung Moon; Ki-Yeon Yoo; Jung Hoon Choi; Ok Kyu Park; In Koo Hwang; Youdong Sohn; Joong Bum Moon; Jun Hwi Cho; Moo-Ho Won
Journal:  Brain Res       Date:  2010-04-25       Impact factor: 3.252

5.  Alginate encapsulated BDNF-producing fibroblast grafts permit recovery of function after spinal cord injury in the absence of immune suppression.

Authors:  Christopher A Tobias; Steve S W Han; Jed S Shumsky; Duckhyun Kim; Maureen Tumolo; Nikhil O Dhoot; Margaret A Wheatley; Itzhak Fischer; Alan Tessler; Marion Murray
Journal:  J Neurotrauma       Date:  2005-01       Impact factor: 5.269

Review 6.  Neuroinflammation in spinal cord injury: therapeutic targets for neuroprotection and regeneration.

Authors:  Jessica K Alexander; Phillip G Popovich
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

7.  Clodronate inhibits the secretion of proinflammatory cytokines and NO by isolated microglial cells and reduces the number of proliferating glial cells in excitotoxically injured organotypic hippocampal slice cultures.

Authors:  Faramarz Dehghani; Ariane Conrad; Angelika Kohl; Horst-Werner Korf; Nils P Hailer
Journal:  Exp Neurol       Date:  2004-10       Impact factor: 5.330

8.  Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods.

Authors:  Courtney Paul; Amer F Samdani; Randal R Betz; Itzhak Fischer; Birgit Neuhuber
Journal:  Spine (Phila Pa 1976)       Date:  2009-02-15       Impact factor: 3.468

Review 9.  Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1.

Authors:  Anna Heile; Thomas Brinker
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 10.  Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury.

Authors:  Andrew D Gaudet; Phillip G Popovich; Matt S Ramer
Journal:  J Neuroinflammation       Date:  2011-08-30       Impact factor: 8.322

View more
  3 in total

Review 1.  Recent Advances in the Use of Algal Polysaccharides for Skin Wound Healing.

Authors:  Suneel Kumar; Ileana Marrero-Berrios; Maciej Kabat; Francois Berthiaume
Journal:  Curr Pharm Des       Date:  2019       Impact factor: 3.116

2.  Identification of IL-1β and LPS as optimal activators of monolayer and alginate-encapsulated mesenchymal stromal cell immunomodulation using design of experiments and statistical methods.

Authors:  Andrea Gray; Timothy Maguire; Rene Schloss; Martin L Yarmush
Journal:  Biotechnol Prog       Date:  2015-05-28

3.  Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Authors:  Maciej Kabat; Ivan Bobkov; Suneel Kumar; Martin Grumet
Journal:  Stem Cells Transl Med       Date:  2019-12-05       Impact factor: 6.940

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.